Adler, S., and H. Huang. Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 287: F907-F913, 2004; doi:10.1152/ajprenal.00060.2004.-Oxidant stress is an important contributor to renal dysfunction and hypertension. We have previously demonstrated that regulation of renal oxygen consumption by nitric oxide (NO) is impaired in the kidney of spontaneously hypertensive rats (SHR) due to increased superoxide production. We further explored the mechanisms of enhanced oxidant stress in the kidney of SHR. Suppression of cortical oxygen consumption by bradykinin (BK) or enalaprilat (Enal), which act through stimulation of endogenous NO, was impaired in SHR (BK: Ϫ14.1 Ϯ 1.2%; Enal: Ϫ15.5 Ϯ 1.2%) and was restored by addition of apocynin, an inhibitor of assembly of the NAD(P)H oxidase complex (BK: Ϫ21.0 Ϯ 0.6%; Enal: Ϫ25.3 Ϯ 1.4%), suggesting this as the source of enhanced superoxide production. Addition of an angiotensin type 1 receptor blocker, losartan, also restored responsiveness to control levels (BK: Ϫ22.0 Ϯ 1.1%; Enal: Ϫ23.6 Ϯ 1.3%), suggesting that ANG II is responsible for enhanced oxidase activity. A similar defect in responsiveness to BK and Enal could be induced in Wistar-Kyoto kidneys by ANG II and was reversed by a superoxide scavenger (tempol), apocynin or losartan. Immunoblotting of cortical samples demonstrated enhanced expression of endothelial NO synthase (eNOS 1.9ϫ) and NAD(P)H oxidase components (gp91 phox 1.6ϫ and Rac-1 4.5ϫ). Expression of SOD-1 and -2 were unchanged, but SOD-3 was significantly decreased in SHR (0.5ϫ). Thus NO bioavailability is impaired in SHR owing to an ANG II-mediated increase in superoxide production in association with enhanced expression of NAD(P)H oxidase components, despite increased expression of eNOS. Loss of SOD-3, an important superoxide scavenger, may also contribute to enhanced oxidant stress. nitric oxide; oxygen radicals; renal physiology ENHANCED LEVELS OF OXYGEN radicals, leading to a state of oxidant stress, have been shown to be present in many disease states characterized by endothelial dysfunction and vascular injury, including diabetes, hypertension, and chronic renal insufficiency, both in animal models and in humans (14, 15, 22, 26 -28, 37). The rapid interaction of superoxide with nitric oxide (NO) results in the production of peroxynitrite, another harmful radical, and the destruction of NO, decreasing NO bioavailability in situations of oxidant stress (10, 25). Decreased availability of NO, resulting in vasoconstriction and loss of endothelium-mediated vasodilation, has been documented in models of hypertension and in human vessels (12, 20, 28, 35) . In particular, in the spontaneously hypertensive rat (SHR) model, the contribution of oxidant stress to the development of hypertension has been suggested in studies demonstrating amelioration or reversal of hypertension by the use of oxygen radical scavengers (27, 28, 37) , and we have demonstrated a decrease in NO bioavailability due to superoxide in
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Levels of oxidant stress are determined by the rates of oxygen radical production and scavenging. The discovery of homologs of the phagocyte NADPH oxidase that are expressed in blood vessels and organs such as the kidney has allowed further characterization and a better understanding of the sources of oxygen radicals other than white blood cells (8, 9, 19, 29) . ANG II has been found to be a major stimulus for oxygen radical production via stimulation of these oxidases, defining another mechanism for its injurious effects (19, 23) . Possibly of equal importance in the control of oxidant stress and nitric oxide bioavailability are oxygen radical scavenging mechanisms, such as the superoxide dismutases, which also play an important role in ameliorating hypertension (4, 17) .
We have previously shown that there is impaired regulation of renal O 2 consumption in SHR in response to stimulators of NO production (2) . Experiments with the superoxide scavenger tempol suggested that increased superoxide levels lead to decreased NO bioavailability in these animals (2) . Other studies have suggested vascular and renal oxidases as sources of enhanced oxidant stress in hypertension and other disease states (9, 19, 23) . We hypothesized that the enhanced oxidant stress in these animals, leading to decreased NO and possibly potentiating hypertension, was due to enhanced oxygen radical production by the NAD(P)H oxidase complex or decreased scavenging of superoxide by endogenous systems. We also speculated that ANG II played a role in the development of oxidant stress. The studies presented here tested these possibilities in isolated kidney tissue from SHR.
MATERIALS AND METHODS
Reagents. Bradykinin, enalaprilat, S-nitroso-N-acetylpenicillamine (SNAP), N-nitro-L-arginine methyl ester (L-NAME), 4-hydroxy-2,2,6,6-tetramethyl piperidine-1-oxyl (tempol), sodium succinate, and sodium cyanide were purchased from Sigma (St. Louis, MO). 4-Hydroxy-3-methoxyacetophenone (apocynin) was purchased from Fluka (Sigma). Losartan (DuP 753) was a gift from DuPont Pharmaceutical (Wilmington, DE). Affinity-purified monoclonal mouse antibodies to endothelial nitric oxide synthase (eNOS/NOS type III), manganese containing SOD (MnSOD; SOD-2), and gp91 phox were purchased from BD Transduction Laboratories (San Diego, CA). Affinity-puri-fied polyclonal antibody (from rabbit) to Rac-1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibody (from sheep) to Cu/Zn SOD (SOD-1) was purchased from Calbiochem (La Jolla, CA). Affinity-purified polyclonal antibody (from rabbit) to extracellular SOD (ecSOD; SOD-3) was a gift from Dr. Wei Wang (Univ. of Colorado Health Sciences Center, Denver, CO). Donkey anti-mouse and anti-rabbit IgG conjugated to horseradish peroxidase were purchased from Sigma.
Animals. Male SHR and Wistar-Kyoto rats (WKY) were purchased from Taconic Farms (Germantown, NY) at 10 wk of age and studied after 1 wk of acclimatization. Rats were maintained on a standard rat chow with 0.4% sodium content (Laboratory Rodent Diet, Richmond, IN) and allowed free access to food and water until the day of study. After death, the left kidneys were removed, decapsulated, and weighed. Tissue samples from the right kidney cortex were snapfrozen in liquid nitrogen and stored at Ϫ80°C for measurement of eNOS, SOD-1, -2, and -3, gp91
phox , and Rac-1 levels (see below mol/l) were added at the end of each experiment to confirm that changes in O2 consumption originated from mitochondrial respiration. Renal cortical O 2 consumption was calculated as the rate of decrease in O 2 concentration, assuming an initial O2 concentration of 224 nmol/ml (calculated from O 2 solubility at 37°C and 1 atm), and is expressed as nanomoles O 2 consumed per minute per gram of tissue. O 2 consumption due to the electrode is Ͻ5% of that observed in the presence of tissue. The effects of drugs used on O 2 consumption are expressed as percent change from baseline O 2 consumption. Baseline O 2 consumption was measured in the cortex in the absence and presence of L-NAME (10 Ϫ3 mol/l) in each group. Effect of agonists of NO production on O 2 consumption. Bradykinin or enalaprilat at concentrations of 10 Ϫ7 -10 Ϫ4 mol/l was added in a cumulative concentration-dependent manner. They were used to measure the effects of stimulation of endogenous NO production on renal O2 uptake. The response to these drugs was also examined after preincubation with the NOS inhibitor L-NAME (10 Ϫ3 mol/l) to verify the role of NO production by NOS in the regulation of O 2 uptake. Each drug was assayed using tissue from six or seven rats in the presence or absence of L-NAME. Changes in O2 consumption in response to bradykinin and enalaprilat were also assessed in the presence of the superoxide dismutase mimetic tempol (10 Ϫ3 mol/l), the ANG II type I receptor (AT 1R)-antagonist losartan (10 Ϫ6 mol/l), and the NAD(P)H oxidase inhibitor apocynin (10 Ϫ5 mol/l) using tissue from SHR and WKY rats (n ϭ 6 for each). In separate experiments, tissue from WKY rats was preincubated with ANG II (10 Ϫ8 mol/l) before the addition of agonists and inhibitors (n ϭ 6).
Effect of NO donor on O2 consumption. SNAP at concentrations of 10
Ϫ7 -10 Ϫ4 mol/l was added in a cumulative concentration-dependent manner to assess the effects of exogenous NO on renal cortical O2 uptake. The response to SNAP was also examined after preincubation with L-NAME (10 Ϫ3 mol/l). Each condition was tested in six or seven rats from each group.
Immunoblotting of proteins. Samples of renal cortex were pulverized in liquid nitrogen and homogenized in 5 vol of lysis buffer (0.05 M Tris ⅐ HCl, pH 7.2, 1 mM EDTA, 0.01 M dithiothreitol, 1 mg/ml PMSF, 100 g/ml leupeptin, 100 g/ml soybean trypsin inhibitor, and 20 g/ml aprotinin, volume ϭ 5ϫ tissue weight) followed by sonication for 1 min at 4°C. Lysates were centrifuged at 10,000 g for 10 min at 4°C and stored at Ϫ80°C until use. Protein content of supernatants was measured using a Bio-Rad protein assay (Bio-Rad Laboratories).
Samples of tissue lysate (100 g of protein) were loaded into individual lanes, subjected to electrophoresis on 8 or 15% polyacrylamide gels, and electrophoretically transferred from the gels to polyvinylidene difluoride membranes (Amersham Pharmacia Biotech) using a semidry transfer cell (Bio-Rad). After at least 1 h of blocking with 5% milk/PBS, membranes were incubated with antibodies to eNOS, SOD-1, SOD-2, SOD-3, gp91
phox , or Rac-1 in 1% milk/PBS at 4°C overnight. After being washed, membranes were incubated with horseradish peroxidase-conjugated second antibodies to mouse, rabbit, or sheep IgG in 1% milk/PBS at room temperature for 2 h. Membranes were also probed with antibody to ␤-actin (Novus Biologicals, Littleton, CO) to correct for differences in protein loading. Sites of antibody-antigen reaction were observed using Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) before exposure to X-ray film (Kodak, Rochester, NY).
The relative intensities of bands in autoradiograms were determined on an AlphaImager 2000 documentation and analysis system (Alpha Innotech, San Leandro, CA) followed by analysis using image software. Band intensity for each measured protein was divided by the intensity of the corresponding ␤-actin band to correct for any differences in protein loading.
Statistical analysis. All data are expressed as means Ϯ SE. Statistical analysis of baseline O 2 consumption and densities of protein bands was performed using Student's t-test. Changes in O2 consumption caused by drug treatment were analyzed using two-way ANOVA followed by multiple comparisons using the Tukey test (Sigma-Stat, SPSS-Science, Chicago, IL). Statistical significance was achieved at P Ͻ 0.05.
RESULTS

Baseline renal cortical O 2 consumption.
Baseline renal cortical O 2 consumption was similar in the two groups, in agreement with our previously published results (2) mol/l) produced significant, concentration-dependent decreases in renal cortical O 2 consumption in WKY and SHR rats (WKY: from Ϫ1.3 Ϯ 0.9 to Ϫ25.3 Ϯ 2.3%, n ϭ 6; SHR: from Ϫ0.3 Ϯ 0.3 to Ϫ14.1 Ϯ 1.2%, n ϭ 7). The depression of renal cortical O 2 consumption by bradykinin was significantly less in SHR than WKY rats (P Ͻ 0.05), confirming previous observations (2) (Fig. 1A) . Similarly, the angiotensin-converting enzyme inhibitor enalaprilat (10 Ϫ7 -10 Ϫ4 mol/l), which also stimulates endogenous NO production, caused concentrationdependent decreases in renal cortical O 2 consumption in WKY and SHR rats (WKY: from Ϫ1.0 Ϯ 0.6 to Ϫ25.6 Ϯ 1.4%, n ϭ 6; SHR: from 0 Ϯ 0 to Ϫ15.5 Ϯ 1.2%, n ϭ 7), with a significantly lower effect in SHR than WKY rats (P Ͻ 0.05) (Fig. 1B) , confirming previous observations. Addition of L-NAME significantly attenuated the effects of bradykinin and enalaprilat only in WKY rats, suggesting diminished production of NO by NOS in SHR (data not shown). The addition of tempol restored responsiveness to inhibition of O 2 consumption in SHR to levels seen in WKY rats, confirming that destruction of NO by superoxide accounts for decreased NO bioavailability in SHR, as we have previously suggested (data not shown) (2) .
Effect of apocynin on renal cortical O 2 consumption. Because scavenging of superoxide with tempol had restored the ability of bradykinin and enalaprilat to suppress renal cortical O 2 consumption in SHR, we explored the source of increased superoxide production in these animals using apocynin, an inhibitor of NAD(P)H oxidase assembly. Bradykinin and enalaprilat both decreased O 2 consumption significantly more in WKY rats than in SHR (Fig. 2) . Addition of apocynin significantly augmented the suppression of O 2 consumption by bradykinin ( Fig. 2A) and enalaprilat (Fig. 2B ) in SHR rats to a level that was not different from that in WKY rats (bradykininϩapocynin in WKY: from Ϫ0.0 Ϯ 0.0 to Ϫ22.6 Ϯ 1.7%, n ϭ 6, SHR: from Ϫ0.6 Ϯ 0.6 to Ϫ21.0 Ϯ 0.6%, n ϭ 7, P Ͼ 0.05; enalaprilatϩapocynin in WKY: from Ϫ1.2 Ϯ 0.7 to Ϫ24.6 Ϯ 1.2%, n ϭ 6, SHR: from Ϫ0.9 Ϯ 0.7 to Ϫ25.3 Ϯ 1.4%, n ϭ 7, P Ͼ 0.05).
Effect of angiotensin blockade on renal cortical O 2 consumption. Because ANG II has been implicated in increases in superoxide production, we explored the effect of blocking ANG II action with the AT 1 -R antagonist losartan. Renal cortical tissue was incubated with losartan (10 Ϫ6 mol/l) before performance of dose-response curves. Inhibition of renal cortical O 2 consumption by bradykinin and enalaprilat was significantly augmented by losartan in SHR but not WKY rats (Fig. 3) . In the presence of losartan, the response in SHR was not significantly different from that in WKY animals (bradykininϩlosartan in WKY: from Ϫ1.4 Ϯ 0.7 to Ϫ23.5 Ϯ 1.6%, n ϭ 6, SHR: from 0 Ϯ 0 to Ϫ22.0 Ϯ 1.1%, n ϭ 7, P Ͼ 0.05; enalaprilatϩlosartan in WKY: from Ϫ2.0 Ϯ 0.7 to Ϫ24.6 Ϯ 1.5%, n ϭ 6, SHR: from Ϫ0.7 Ϯ 0.5 to Ϫ23.6 Ϯ 1.3%, n ϭ 7, P Ͼ 0.05).
Effect of NO donor SNAP on renal cortical O 2 consumption. Administration of cumulative doses of the NO donor SNAP (10 Ϫ7 -10 Ϫ4 mol/l) decreased renal cortical O 2 consumption similarly in WKY and SHR, demonstrating no inherent differences between the strains in responsiveness of O 2 consumption to exogenous NO (Fig. 4) . Addition of tempol (data not shown), apocynin, losartan, or L-NAME did not affect responsiveness to SNAP.
Effect of ANG II on renal cortical O 2 consumption.
Because experiments with losartan suggested ANG II as a cause of increased superoxide production in SHR, we explored the effect of ANG II on renal cortical O 2 consumption in WKY rats. Preincubation of renal cortical tissue from WKY rats with ANG II (10 Ϫ8 mol/l) significantly suppressed responsiveness to inhibition of renal cortical O 2 consumption by bradykinin (bradykinin: from 0 Ϯ 0 to Ϫ23.5 Ϯ 1.0%, n ϭ 6; Fig. 1 . Effect of cumulative doses of bradykinin (A) or enalaprilat (B) on renal cortical O2 consumption in Wistar-Kyoto (WKY; F) and spontaneously hypertensive rats (SHR; OE). Both drugs caused significant dose-dependent decreases in O2 consumption that were significantly less in SHR. *P Ͻ 0.05 vs. WKY rats.
Fig. 2. Effect of inhibition of NAD(P)H oxidase with apocynin on inhibition of renal cortical O2 consumption by cumulative doses of bradykinin (A) or enalaprilat (B)
. The response to both drugs was significantly less in SHR (OE) than in WKY (F) rats. Addition of apocynin had no effect in WKY rats (E) but restored responsiveness in SHR (‚). *P Ͻ 0.05 vs. SHR with apocynin. bradykininϩANG II: from 0 Ϯ 0 to Ϫ10.7 Ϯ 3.0%, n ϭ 6, P Ͻ 0.05) (Fig. 5A) . Scavenging of superoxide with tempol, inhibition of NAD(P)H oxidase with apocynin, or blockade of the AT 1 R with losartan all restored the responsiveness to inhibition of renal cortical O 2 consumption by bradykinin toward the effect seen in control WKY despite the presence of ANG II (Fig. 5B) .
Levels of renal cortical proteins (NOS, SOD, gp91
phox , Rac-1). Expression of several proteins involved in NO production and metabolism of oxygen radicals were measured in samples of renal cortex from WKY and SHR rats (Fig. 6) . Despite evidence of decreased NO bioavailability in SHR, levels of eNOS protein in renal cortex of SHR are significantly increased compared with WKY rats ( SHR: 3.02 Ϯ 0.53, n ϭ 7; WKY: 1.58 Ϯ 0.07, n ϭ 6, P Ͻ 0.05). A similar, albeit smaller, increase was seen in medullary eNOS (data not shown). Levels of SOD-1 and SOD-2 were similar in both groups of rats (SOD-1: SHR: 0.44 Ϯ 0.08, n ϭ 7; WKY: 0.59 Ϯ 0.08, n ϭ 7, P Ͼ 0.05; SOD-2: SHR: 0.42 Ϯ 0.12, n ϭ 6; WKY: 0.42 Ϯ 0.05, n ϭ 6, P Ͼ 0.05), but levels of extracellular SOD (SOD-3) were significantly reduced in SHR (SHR: 0.32 Ϯ 0.04, n ϭ 7; WKY: 0.62 Ϯ 0.08, n ϭ 7, P Ͻ 0.01). Two components of the NAD(P)H oxidase complex, gp91 phox and Rac-1, are both significantly increased in SHR rats (gp91 phox : SHR: 3.13 Ϯ 0.49, n ϭ 7; WKY: 2.0 Ϯ 0.09, n ϭ 7, P Ͻ 0.05; Rac-1: SHR 1.38 Ϯ 0.28, n ϭ 7; WKY: 0.31 Ϯ 0.05, P Ͻ 0.01).
DISCUSSION
The studies presented here confirm our previous work in the SHR kidney (2), namely, of decreased NO bioavailability, reflected as an impairment of regulation of renal O 2 consumption, and again suggest excess superoxide production as the cause. We have used the regulation of renal oxygen consumption by NO as a direct measure of a NO effect in renal cortex in vitro in the absence of glomerular filtration, thus demonstrating a basic change in renal metabolism in SHR independent of the workload of sodium transport. Decreased NO bioavailability occurs despite increased expression of eNOS, the major NOS isoform responsible for regulation of renal oxygen consumption by NO (1) . The data also suggest that the major source of superoxide is the NAD(P)H oxidase complex and that ANG II plays an important role in the stimulation of superoxide production. Finally, we document that in addition to increased expression of proteins involved in the assembly of the NAD(P)H oxidase complex in the kidney, there is loss of an important antioxidant defense, extracellular SOD (SOD-3). The end result of these processes is an increase in the level of oxidant stress mediated mainly through an effect of ANG II.
Enhanced production of superoxide has been demonstrated in numerous models of hypertension, including those due to partial nephrectomy, lead-induced hypertension, salt-sensitive hypertension, and the SHR (2, 14, 20, 21, 26 -28, 35, 37) . Evidence of enhanced oxidative stress has been obtained in Fig. 3 . Effect of blockade of the AT1 receptor with losartan on inhibition of renal cortical O2 consumption by cumulative doses of bradykinin (A) or enalaprilat (B). The response to both drugs was significantly less in SHR (OE) than in WKY (F) rats. Losartan had no effect in WKY (E) but restored responsiveness in SHR (‚). *P Ͻ 0.05 vs. SHR with losartan. humans with renovascular hypertension and appears to decrease after angioplasty (15, 22) . Interestingly, patients with essential hypertension did not have enhanced excretion of a marker of in vivo lipid peroxidation despite a similar degree of hypertension (22) . Segments of internal mammary artery and saphenous veins removed from patients undergoing coronary artery revascularization, most of whom were hypertensive, displayed NADH-and NAD(P)H-enhanced superoxide production, which was reversed by addition of apocynin or SOD (12) . Suppression of superoxide production resulted in increased NO bioavailability and improved endothelium-mediated vasorelaxation via NO. Similarly, Guzik et al. (11) demonstrated superoxide production in all three vessel layers (adventitia, media, endothelium) but also noted that NO production scavenges superoxide, suggesting a much more complex interaction within the vessel wall.
Evidence that scavenging of NO by superoxide contributes to hypertension comes from experiments demonstrating increased NO bioavailability and decreased blood pressure after manipulations that decrease oxygen radical levels. Administration of superoxide scavengers ameliorates hypertension in SHR and salt-sensitive hypertension (21, 27, 28, 37) . Production of superoxide in the renal cortex and medulla in Dahl saltsensitive rats was decreased by tempol in association with a drop in blood pressure (21) . Life-long supplementation with antioxidants also delays the onset of hypertension, as well as ameliorating its severity, in SHR (42), along with decreasing markers of oxidative stress. Directly decreasing production of superoxide with a highly specific inhibitor of vascular NAD(P)H oxidase decreases blood pressure in a mouse model of hypertension induced by ANG II infusion (24) . Finally, scavenging of superoxide by SOD leads to decreases in blood pressure. This is demonstrated by significantly increased blood pressure in SOD-3-deficient mice with one clipped kidney or after infusion with ANG II compared with controls. (17) . Infusion of recombinant SOD-3 into ANG II-treated mice rapidly lowered blood pressure (17) . Transfection of SHR with the gene for human SOD-3 similarly lowered blood pressure (4). This was accompanied by improvement of acetylcholinemediated vascular relaxation, suggesting increased availability of endothelium-generated NO.
There are several sources of increased superoxide production potentially implicated in vascular pathology, including xanthine oxidase, cytochrome P-450, uncoupled NOS, and the NAD(P)H oxidases (19) . A kidney specific oxidase (Renox or NOX-4) has been described but is also found in vascular smooth muscle cells (8, 13, 29) . Previous work in the SHR has documented overexpression of several components of the NAD(P)H oxidase complex through measurement of mRNA and/or protein levels by immunoblotting (3, 30, 42) . Chabrashvili et al. (3) found expression of the p22 phox , p47 phox , and p67 phox subunits of the NAD(P)H complex in the renal vasculature and elements of the distal tubule (starting at the thick ascending limb) in the kidney of SHR with significantly increased levels of p47-and p67 phox in SHR compared with WKY animals. Zhan et al. (42) described increased levels of gp91 phox , the catalytic subunit of the complex, and p22 phox in the renal cortex of SHR. In the latter studies, the feeding of antioxidants not only reduced hypertension and oxidative stress but also decreased the level of expression of these subunits. Our work confirms overexpression of gp91 phox and the small G protein Rac-1 that is necessary for activation of the oxidase. In thoracic aortas of SHR, increased levels of p22 phox were also detected (30) . Overexpression of these components, along with the beneficial effects of apocynin, an inhibitor of assembly of the complex, on the responsiveness of O 2 consumption to stimulators of NO production, suggests that the NAD(P)H complex is an important source of oxygen radicals in SHR.
Another potential source of superoxide is uncoupled NOS. When levels of arginine or tetrahydrobiopterin (BH 4 ) are low, NOS activation may favor production of superoxide rather than NO (32, 41) . Evidence of enhanced oxygen radical production by NOS has been found in aortas from young, prehypertensive SHR (5), and administration of BH 4 to SHR animals suppresses the development of hypertension as well as decreases superoxide production by aortic segments (16) . Levels of NOS isoforms in the kidney have been reported to be elevated in SHR, including inducible NOS, neuronal NOS, and eNOS (33, 40) . We have confirmed elevated eNOS expression in the renal cortex of SHR but have been unable to detect either inducible NOS or neuronal NOS in cortical samples. While we have not directly studied the possibility that uncoupled NOS in the renal cortex leads to the observed increase in oxidant stress, the ability of apocynin to completely reverse the defect seen in SHR suggests that NAD(P)H oxidase is the most important source of superoxide in the kidney.
The ability of the AT 1 R antagonist losartan to restore the effect of bradykinin and enalaprilat on the regulation of renal O 2 consumption suggests a role of ANG II in mediating enhanced oxidant stress in SHR. This is further supported by the observation of induction of a similar defect in kidney from WKY rats by incubation with ANG II, a defect again reversed by superoxide scavenging with tempol or inhibition of NAD(P)H oxidase assembly with apocynin. ANG II is known to stimulate both activity and expression of NAD(P)H oxidase (9, 13, 19) , which in turn reduces NO availability through scavenging. O 2 utilization in the kidney of SHR for sodium transport has been shown to be less efficient than in WKY rats (38) , an observation consistent with our finding of impaired regulation of renal O 2 consumption in SHR and decreased NO bioavailability (2) . This defect is largely reversed by the AT 1 R blocker candesartan in vivo (39) , suggesting that activation of the AT 1 R mediates the increased O 2 consumption. Our data further support a role in vitro for an AT 1 R-mediated increase in renal oxidant stress, leading to decreased NO bioavailability in the SHR.
Of interest, we also found that levels of extracellular SOD were reduced by ϳ50% in SHR, potentially contributing further to oxidant stress in these animals. Studies in mice lacking either SOD-3 or Cu/Zn SOD (SOD-2) have suggested that deficiency of either of these enzymes can lead to increased superoxide levels and loss of NO, leading to decreased endothelium-mediated vasodilatation (6, 17) , although basal blood pressure was not elevated in either group of deficient animals. Under stress, induced by clipping of one kidney or ANG II infusion, blood pressure was higher in SOD-3-deficient animals (17) . Overexpression of human SOD-3 in SHR also leads to lowering of blood pressure (4), further supporting the importance of superoxide scavenging mechanisms in responding to oxidant stress. Another study of SOD expression in the aorta of SHR found increased levels of SOD-1 and SOD-2, whereas SOD-3 was not measured (30) . These animals were, however, much older than the ones studied here, and these results might represent a change with aging or different regulation of SODs in the vessel wall vs. the kidney. Because expression of SOD-3 in mice is regulated by NO, the loss of SOD-3 in SHR may be a secondary, albeit aggravating, factor (7) . In other models with enhanced oxidant stress, namely 5 ⁄6 nephrectomy, salt loading, and lead-induced hypertension, renal expression of SOD-1 has been found to be decreased or increased, whereas SOD-2 was decreased or unchanged (18, 34, 36) . Thus a general pattern of response of SOD expression in situations of oxidant stress is not apparent.
In summary, we have further confirmed the role of enhanced intrarenal superoxide production in limiting NO availability in the kidney in the SHR model of hypertension. We have demonstrated that enhanced expression and activation of elements of the NAD(P)H complex occur in these animals, contributing to oxidant stress, along with loss of an important counterregulatory element, SOD-3. Loss of NO occurs despite enhanced expression of eNOS, which in itself could be a response to lower levels of NO. Finally, an important role of stimulation of the AT 1 R by ANG II in the enhanced oxidant stress that occurs in these animals has been demonstrated.
